Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Net Margin: 2014-2025

Historic Net Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -49.67%.

  • Viridian Therapeutics, Inc.\DE's Net Margin rose 8889684.00% to -49.67% in Q3 2025 from the same period last year, while for Sep 2025 it was -427.30%, marking a year-over-year increase of 8463528.00%. This contributed to the annual value of -89,387.09% for FY2024, which is 1367562.00% down from last year.
  • Viridian Therapeutics, Inc.\DE's Net Margin amounted to -49.67% in Q3 2025, which was up 99.96% from -134,313.33% recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Net Margin peaked at -49.67% during Q3 2025, and registered a low of -134,313.33% during Q2 2025.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Net Margin averaged around -83,417.42%, with its median value being -88,946.51% (2024).
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Net Margin crashed by 6,495,647bps in 2023 and then skyrocketed by 8,889,684bps in 2025.
  • Viridian Therapeutics, Inc.\DE's Net Margin (Quarterly) stood at -13,526.17% in 2021, then crashed by 3,007,859bps to -43,604.76% in 2022, then tumbled by 4,925,635bps to -92,861.11% in 2023, then tumbled by 1,794,861bps to -110,809.72% in 2024, then skyrocketed by 8,889,684bps to -49.67% in 2025.
  • Its last three reported values are -49.67% in Q3 2025, -134,313.33% for Q2 2025, and -120,711.11% during Q1 2025.